Story perspectives

Monsanto Proposes $7.25B Settlement Over Roundup Cancer Claims

2/17/2026

39 4

Summary

Story summary

Monsanto, a Bayer subsidiary, proposed a $7.25 billion settlement to resolve lawsuits alleging that Roundup weedkiller causes non-Hodgkin lymphoma.
The settlement comes as a Supreme Court case focuses on Monsanto's obligation to warn consumers about cancer risks.
CEO Bill Anderson said a favorable ruling could affect cases beyond the settlement.
Anderson stated the settlement aims to end litigation uncertainty and refocus Monsanto on its mission, including health and agriculture advancements.

History

Historical Context

The legal battles surrounding Monsanto's Roundup began intensifying after the International Agency for Research on Cancer classified glyphosate as "probably carcinogenic" in 2015. In 2018, a jury awarded $289 million to Dewayne Johnson, a groundskeeper with cancer, highlighting the company's failure to warn consumers. By 2020, Bayer, which acquired Monsanto, faced over 125,000 lawsuits and proposed a $7.25 billion settlement to address ongoing litigation.

1 of 2

Story summary

Monsanto, a Bayer subsidiary, proposed a $7.25 billion settlement to resolve lawsuits alleging that Roundup weedkiller causes non-Hodgkin lymphoma.
The settlement comes as a Supreme Court case focuses on Monsanto's obligation to warn consumers about cancer risks.
CEO Bill Anderson said a favorable ruling could affect cases beyond the settlement.
Anderson stated the settlement aims to end litigation uncertainty and refocus Monsanto on its mission, including health and agriculture advancements.

1 / 2